Nonalcoholic steatohepatitis (NASH) is the former name for metabolic dysfunction-associated steatohepatitis (MASH), a progressive inflammatory fatty liver disease that can advance to fibrosis and cirrhosis.
Oramed Pharmaceuticals experienced a 57.8% surge in short interest in January 2024, reaching 644,912 shares. The company continues to navigate challenges following the failure of its Phase 3 oral insulin trial in early 2023, which caused its stock to plummet over 70%. Oramed maintains focus on its proprietary oral drug delivery technology while exploring strategic alternatives.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07481734 |
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) |
RECRUITING | PHASE2 |
| NCT06692283 |
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH |
WITHDRAWN | PHASE3 |
| NCT06594523 |
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis |
WITHDRAWN | PHASE3 |
| NCT06465186 |
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06365580 |
Dose Escalation Study of Kylo-0603 in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT06342947 |
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) |
COMPLETED | PHASE2 |
| NCT05983328 |
Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT05979779 |
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05877547 |
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) |
COMPLETED | PHASE2 |
| NCT05824156 |
CM-101 in NASH Patients - The SPLASH Study |
COMPLETED | PHASE2 |
